SCHEMBL30511508

SCHEMBL30511508

CC(C)COC(=O)[C@H](C)NP(=O)(Oc1ccc(Br)cc1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.46
▸ MEN1 O00255 5/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CES2 O00748 1/20 0.42
▸ CES1 P23141 1/20 0.42
▸ BCHE P06276 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ ADRB1 P08588 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13469579 0.91 ALDH1A1 (0.47) MAPTMEN1KMT2AALDH1A1CA1
SCHEMBL30511485 0.90 CA1 (0.47) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL30583786 0.89 MEN1 (0.46) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL28542672 0.89 MEN1 (0.46) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL17550476 0.89 MEN1 (0.46) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL30770552 0.87 MEN1 (0.44) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL23358320 0.85 MEN1 (0.47) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL23358321 0.85 MEN1 (0.47) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL23358345 0.85 MEN1 (0.47) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL19361266 0.85 CA1 (0.42) MAPTMEN1KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202850-B2 Cyclobutyl purine derivative or salt thereof FUJIFILM CORPORATION (JP) 2025-01-21 — — US disclosed
EP-3831388-B1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FOR USE IN SUPPRESSING ADENOVIRUS FUJIFILM CORP (JP) 2024-02-28 — — EP disclosed
US-20230295202-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2023-09-21 — — US disclosed
EP-3831836-B1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2023-09-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295202-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF SLC28A1, SLC20A1, SLC29A1 MAPT 4397/4885MEN1 2712/4885KMT2A 4442/4885
US-12202850-B2 Cyclobutyl purine derivative or salt thereof SLC28A1, SLC20A1, SLC29A1 MAPT 4397/4885MEN1 2712/4885KMT2A 4442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback